Transforming Growth Factor-b1 (TGF-b1) inhibits the proliferation of most cells, but stimulates some mesenchymal cell types, including murine NIH3T3 ®broblasts. We show here that TGF-b1 growth stimulation of NIH3T3 ®broblasts is reversed when these cells are transformed by SV40 or are transfected with a plasmid encoding the SV40 Large T antigen. Inversion of the TGF-b1 growth stimulation of NIH3T3 cells is not observed when these cells are transfected with plasmids expressing either a mutant Large T, unable to bind P53, or the E1A adenovirus oncoprotein which binds the retinoblastoma protein pRB but not P53. But when the TGF-b1-growth stimulated cells are transfected with a plasmid expressing a mutant form of Large T capable of binding to P53, but not to pRB, or with one expressing the E1B-55 kD adenovirus oncoprotein, which also binds to P53 but not to pRB, the cells are growth-inhibited by TGF-b1. The cdk inhibitor p21Waf is decreased in TGFb1-stimulated NIH3T3 ®broblasts and increased in TGFb1-inhibited SV40-transformed cells. Finally, we show that T12 ®broblasts, from a P53 knockout mouse, are growth inhibited by TGF-b1 and that they remain so upon transfection with a P53 which is mutant at restrictive temperature, but become growth-stimulated by this factor at permissive temperature when P53 is functional. These data strongly suggest that growthstimulation of ®broblasts by TGF-b1 depends on the presence of a functional P53 protein and that inversion of this response occurs if P53 is absent or inactivated.
Introduction
Transforming Growth Factor-b1 (TGF-b1) exerts three major biological eects; it inhibits or, more rarely, stimulates cell proliferation, it acts as an immunosuppressive agent and it stimulates the formation of the extracellular matrix (for general reviews, see Roberts and Sporn, 1990; MassagueÂ and Polyak, 1995; Alexandrow and Moses, 1995) . Two plasma membrane receptors with serine/threonine kinase activity, type I and type II, are involved in signal transduction of the TGF-b1 response (Derynck, 1994; Ventura et al., 1994; Okadome et al., 1994) . Concerning the bifunctional responses of TGF-b1 on cell proliferation, by far the most attention has been concentrated on clarifying the mechanism whereby it inhibits cell growth (Alexandrow and Moses, 1995) . Successive discoveries have shown that TGF-b1-mediated growth inhibition involves the maintenance of pRB in a hypophosphorylated state by upregulation of two distinct families of cyclin kinase inhibitors, the p21Waf/p27Kip family and the p15/p16 family (reviewed in MassagueÂ and Polyak, 1995) and the expression of certain members of the SMAD protein family (reviewed in Heldin et al., 1997) , which propagate the TGF-b1 signal from the type I receptor at the membrane towards the nucleus thereby regulating gene transcription. In some cell types other signalling molecules may be involved, such as c-myc (Alexandrow and Moses, 1995) and cAMP (Daniel et al., 1987) .
Far less attention has been given to elucidating the mechanism of growth stimulation by TGF-b1, despite the fact that proliferation of several mesenchymal cell types is increased by TGF-b1 (Lawrence, 1995) . One of the most intriguing reports on the bifunctionality of the TGF-b1-mediated growth response was by Hill et al., (1986) , who showed that human embryo ®broblasts from fetuses weighing less than 50 gm were growthstimulated, whereas those from fetuses weighing over 100 gm were growth-inhibited. To our knowledge the mechanism of this switch in the TGF-b1 response has not been elucidated. In the case of murine AKR-2B ®broblasts, their stimulation by TGF-b1 was attributed to the induction of c-sis, which encodes PDGF-B, leading to indirect growth stimulation by the latter factor (Leof et al., 1986) . TGF-b1 also stimulates the proliferation of mouse C3H10T1/2 ®broblasts, but this stimulation does not appear to involve PDGF, since a polyclonal anti-PDGF-AB antibody which inhibits PDGF-BB-induced DNA synthesis in these cells, did not inhibit TGF-b1-induced proliferation (Kim et al., 1993) . It was subsequently shown that TGF-b1 increases phosphorylation of pRB (Kim et al., 1994) and down-regulates the cdk2/cyclin E inhibitor, p27Kip (Ravitz et al., 1995) , in C3H10T1/2 cells, which would allow the G1/S transition. Proliferation of chick embryo ®broblasts is also stimulated by TGF-b1 and in this case it was found that the growth factor increased ornithine decarboxylase activity and polyamine synthesis (Evangelisti et al., 1997) . A report by Watabe et al. (1994) , implicated increased levels of cAMP in the mitogenic eect of TGF-b1 and TGF-b2 on Schwann cells, in that forskolin suppressed this eect. In osteoblasts, a mesenchymal cell type stimulated to proliferate by TGF-b1, it was shown (Machwate et al., 1995) that this growth response involved a rapid, but transient, expression of c-fos mRNA and protein, like that following serum addition.expression of cyclin E (which occurs in some human tumours) in NIH3T3 cells was associated with a decrease in TGF-b1-mediated stimulation of these cells.
Our laboratory previously showed that NIH3T3 mouse ®broblasts were growth-stimulated by TGF-b1 and that c-myc, an intermediate-early response gene, was induced in TGF-b1-treated cells with similar kinetics to those in cells treated with serum and growth factors exerting a direct mitogenic action on cell growth (Benzakour et al., 1992) . We have also shown that the proliferation of human W138 embryo ®broblasts is increased by TGF-b1 (Raynal et al., 1994) and that this growth stimulation is accompanied by decreased expression of p21Waf (Raynal and Lawrence, 1995) . This stimulation of the growth of W138 ®broblasts is inversed when these ®broblasts are transformed by Simian Virus 40 (SV40) and p21Waf expression is increased following TGF-b1 treatment. Here, we report that the TGF-b1-mediated stimulation of proliferation of NIH3T3 ®broblasts is also inversed in their SV40-transformed counterparts and have sought an explanation of this inversion of the TGFb1 growth response. By stably transfecting NIH3T3 ®broblasts with plasmids expressing SV40 wild type Large T antigen (LTag), LTag mutants binding P53 but not pRB or the reverse, the adenovirus E1A or E1B oncoproteins and by using P53-knockout fibroblasts transfected with a temperature-sensitive P53, we show that growth stimulation of these ®broblasts by TGF-b1 requires a wild type P53 and that its absence or inactivation by mutation or by complexing with a viral oncoprotein leads to an inversion of the growth response. Growth stimulation by TGF-b1 of NIH3T3 ®broblasts correlates with a reduced level of p21Waf and a small decrease in p27Kip, whereas growth inhibition by TGF-b1 of their SV40-transformed counterparts correlates with an increased level of p21Waf, without a notable change in p27Kip levels, compared to controls.
Results

Modulation of the TGF-b1 growth response of NIH3T3 cells by SV40
Previously published results from this laboratory have established that mouse NIH3T3 and human embryo WI38 ®broblasts are growth-stimulated by TGF-b1 and that WI38 cells transformed by SV40 are growthinhibited by this factor (Benzakour et al., 1992; Raynal et al., 1994) . Here, we investigated if SV40 modulates the response of NIH3T3 cells to TGF-b1. We ®rst recon®rmed that [ 3 H]thymidine incorporation in previously serum-deprived NIH3T3 cells was strongly stimulated by a 24 h treatment with 2 ng/ml of TGFb1 in the presence of 5% NCS (82% stimulation). In NIH-SV40 cells, an SV40-transformed NIH3T3 cell line, the same treatment induced a reproducible inhibition of [ 3 H]thymidine incorporation (42% inhibition). These stimulatory or inhibitory eects of TGFb1 were con®rmed by cell number counts over a six day period as is shown in Figure 1 , left panel: thus in all cultures starting at 5000 cells/dish, untreated NIH3T3 cells attained 66500+2753 cell and TGF-b1-treated ones 211250+19618 cells, whereas untreated NIH-SV40 cells attained 84000+2040 cells and TGFb1 treated ones only 52625+2444 cells. These eects of TGF-b1 on growth of NIH3T3 cells+SV40 parallel those using WI38 cells+SV40. As shown in Figure 2 , after 24 h TGF-b1 treatment the percent of NIH3T3 cells in G1 was decreased, with a corresponding increase in those in S phase, whereas the contrary applied to the SV40-transformed cells. The possibility that the lower cell number observed in NIH-SV40 cultures treated with TGF-b1 compared with control cultures might be due to apoptosis was eliminated by the results of¯ow cytometry analysis (Table 2) .
Large T antigen alone is sucient for reversion of growth stimulation of NIH3T3 by TGF-b1 NIH-SV40 cells used above were obtained after the transformation of NIH3T3 cells with SV40 virus. To investigate whether Large T antigen (LTag) alone was sucient for the reversion of the NIH3T3 growth response to TGF-b1, we stably cotransfected NIH3T3 cells with an expression vector encoding LTag, together with the pWLneo plasmid. The resulting cell line NIH-LT was tested for the presence of LTag by Western blot analysis using PAb 416, a monoclonal anti-LTag antibody. As shown in Figure 3a , NIH-LT cells, like NIH-SV40 cells, expressed LTag. Neomycin vectortransfected control cells (NIH-neo cells), as well as NIH3T3 cells did not express LTag. By immunoprecipitation analysis using the same antibody (PAb 416), we demonstrate that P53 co-immunoprecipitates with LTag in both NIH-SV40 and NIH-LT cells ( Figure  3b ). This argues in favor of P53 being of the wild type form in these cells.
We next analysed the eects of TGF-b1 on growth response of NIH-neo and NIH-LT cells, by [ 3 H]-thymidine incorporation and cell counts. The results Figure 1 Eect of TGF-b1 on growth of NIH3T3 cells and their derivatives studied by cell number counts. Cells were seeded at 5000/dish (2 cm 2 ) in DMEM+2% NCS and on the next day 2 ng/ml of TGF-b1 or control vehicle (HC1/BSA) were added. These cultures were given a second dose of TGF-b1 (or control) on day 3 and cell counts were made on day 6. Each given value is the mean+s.d. of cell counts in 4 wells; the observed dierences between TGF-b1 treated cells and their controls were statistically signi®cant according to the t-test (P50.001) (Figure 1) . These results show that with respect to the TGF-b1 response, LTagtransfected cells behave like SV40-transformed cells.
TGF-b1 does not modulate the level of P53
Previously, we reported that TGF-b1 did not aect the level of P53 protein synthesis in WI38 cells or in SV40-transformed WI38 cells, although it did enhance dephosphorylation of P53 in the latter cells (Raynal et al., 1994) . Similarly, here in immunoprecipitation experiments, TGF-b1 had no eect on the level of p53 protein synthesis in NIH3T3, NIH-SV40 (Figure 4a ), NIH-neo or NIH-LT cells (Figure 4b ), although it decreased by 25% the level of p53 phosphorylation in NIH-SV40 cells (not shown). Thus the results obtained here with murine cells parallel those obtained using human ®broblasts.
Inversion of growth stimulation of NIH3T3 by TGF-b1 occurs when LTag complexes with P53 protein Both P53 and pRB form a complex with LTag (for a general review, Manfredi and Prives, 1994) . To test if S-methionine for 2 h and subjected to immunoprecipitation analysis as described in Materials and methods. Immunoprecipitations were carried out using the same amount of acid-insoluble radioactive counts from each lysate in each panel shown 
Cells were treated with 2 ng/ml TGF-b1 or control vehicle (HCl/ BSA). Incorporation of [ 3 H]thymidine was measured after 24 h treatment, as described in Materials and methods. Each given value is the mean+s.d. of four independent experiments Cells were treated with TGF-b1 (2 ng/ml) or control vehicle (HCl/ BSA) at indicated times and labelled with 1 ng/ml Hoechst 33342 as described in Materials and methods and analysed by¯ow cytometry. Each given value is the mean+s.d. of three independent experiments TGF-b1-growth stimulation of fibroblasts requires p53 F Dkhissi et al the inversion of the mitogenic response of NIH3T3 cells to TGF-b1 by LTag was related to the complexing of P53 protein or to pRB, we stably transfected them with expression vectors encoding LTag-K1, a mutant form of LTag which binds P53 but is defective in binding to pRB (DeCaprio et al., 1988) or LTagdel1137, an aminoterminal deletion mutant defective in binding to P53 protein but which binds to pRB (Pipas et al., 1983) . As shown in Figure 5 , by immunoprecipitation using PAb 416 anti-LTag antibody, the resulting cells, NIH-K1 and NIH-del1137, express the corresponding LTag-K1 and LTag-del1137 proteins respectively. LTag-K1 protein but not LTag-del1137 protein is co-immunoprecipitated with P53 protein as is clearly visible in the same ®gure. We checked next, the growth response of these cells to TGF-b1. As can be seen in Table 1 . In cell number counts over a 6 day period, untreated NIH-K1 cells attained 119250+3682 and TGF-b1-treated ones only 63250+2240 cells, whereas untreated NIH-del1137 cells attained 93750+4806 and TGF-b1 treated ones 158750+15500 cells (Figure 1 ). These results indicate that LTag inverses the stimulatory growth response of NIH3T3 ®broblasts to TGF-b1 by complexing P53, but not when it complexes with pRB.
E1B-55 kd but not E1A adenovirus protein reverses the growth response of NIH3T3 to TGF-b1
To determine whether the inversion of the stimulatory growth response of NIH3T3 to TGF-b1 occurs when P53 is inactivated by complexing with another viral oncoprotein, we stably transfected NIH3T3 cells with the pRSVneo-5SVE1B plasmid encoding the E1B-55 kd protein of adenovirus type 5, which is known to bind and inactivate P53 (Sarnow et al., 1982; Zantema et al., 1985) and compared their response to TGF-b1 with cells stably transfected with a plasmid encoding the E1A protein of adenovirus type 2 which does not bind to P53 but binds to pRB (Whyte et al., 1988) . The resulting cells, NIH-E1B and NIH-E1A, were tested for oncoprotein expression and co-immunoprecipitation of P53 by Western blot and immunoprecipitation analysis respectively. As illustrated in Figure 6a , NIH-E1A cells express a 46 kd protein which corresponds to E1A oncoprotein and NIH-E1B cells express a 55 kd protein which corresponds to E1B oncoprotein ( Figure  6b ). In NIH-E1B cells but not in NIH-E1A cells, P53 co-immunoprecipitates with the corresponding oncoprotein ( Figure 6c ).
We next analysed the TGF-b1 growth response of these two new cell types by measurement of DNA synthesis and cell number counts as above. As shown in Table 1, [ 3 H]thymidine incorporation is reduced 34% in NIH-E1B cells and stimulated 57% by TGF-b1 treatment of NIH-E1A cells. By cell counts, untreated NIH-E1B cells attained 99600+3192 cells and TGFb1-treated ones only 54000+2390 cells, whereas untreated NIH-E1A cells attained 77900+3100 cells and TGF-b1 treated ones 185000+6996 cells. These results con®rm that when P53 is complexed with an oncoprotein, but not pRB, inversion of the stimulatory growth response of NIH3T3 to TGF-b1 occurs and and NIH-SV40 cells were cultured for 24 h in DMEM+5% NCS, then serum deprived overnight to improve cell synchronisation, after which they were treated (+) or not (7) with 2 ng/ml TGF-b1 for 24 h and labelled with 35 Smethionine for 2 h and subjected to immunoprecipitation analysis using PAb 122 antibody as described in Materials and methods. (b) NIH-neo and NIH-LT cells were treated as in (a) and subjected to immunoprecipitation analysis using PAb 122 antibody Figure 5 Immunoprecipitation analysis of LTag. NIH-neo, NIH-K1 and NIH-del1137 cells grown in DMEM+5% NCS were labelled with 35 S-methionine for 2 h and subjected to immunoprecipitation analysis using PAb 416 antibody as described in Materials and methods. Immunoprecipitations were carried out using the same amount of acid-insoluble radioactive counts from each lysate in each panel shown Figure 6 Expression studies of E1A and E1B oncoproteins and their co-immunoprecipitation with P53. (a) NIH-neo and NIH-E1A cells were grown in DMEM+5% NCS and analysed for E1A protein expression by Western blot studies using anti-E1A M73 antibody. (b) NIH-neo and NIH-E1B were tested for E1B expression by Western blot analysis using the monoclonal antibody A1C6. (c) NIH-neo, NIH-E1A and NIH-E1B cells were compared for co-immunoprecipitation of P53 with the corresponding oncoprotein using the monoclonal anti-P53 PAb 122 antibody TGF-b1-growth stimulation of fibroblasts requires p53 F Dkhissi et al that a functional P53 is required for TGF-b1 growthstimulation of NIH3T3 ®broblasts.
P53-knockout T12 murine ®broblasts are growth inhibited by TGF-b1 and become growth stimulated when they express a wild type P53
To support further the notion that a wild type P53 is required for TGF-b1 growth-stimulation of ®broblast cell lines, and that its inactivation or absence results in an inversion of this growth response, we ®rst studied the eect of TGF-b1 on T12 cells, a ®broblastic cell line which lacks P53 (Donehover et al., 1992) . As can be seen in Table 3 , a 24 h treatment of T12 cells with TGF-b1 reduced their DNA synthesis (52% inhibition of [ 3 H]thymidine incorporation). By cell number counts, untreated T12 cells seeded at 5000 cells/dish attained 144000+4403 cells over a 6 day period whereas TGF-b1-treated ones attained only 68800+650 cells (Figure 7 ). This result indicates that when P53 is absent, TGF-b1 inhibits the growth of ®broblasts.
We next studied if the transfection of these cells with P53 modulates the TGF-b1-growth response. For these experiments, we stably transfected T12 cells with the temperature-sensitive murine P53-Val135 construct which expresses a mutant form of P53 at 378C and a wild type P53 at 32.58C (Michalovitz et al., 1990; Milner and Medcalf, 1990) , together with pWLneo plasmid or with this last plasmid alone. As shown in Figure 8 , T12 transfected cells (T12-P53 cells), but not T12-neo control cells, do express P53 at both temperatures with a minute dierence in migration pattern possibly due to a dierence in the P53 phosphorylation level. As shown in Table 3 , DNA synthesis in T12-neo control cells is inhibited at both temperatures (58% and 63% inhibition of [ 3 H]thymidine incorporation at 378C and 32.58C, respectively), whereas in T12-P53 cells maintained at restrictive temperature (378C), DNA synthesis is inhibited (44% inhibition of [ 3 H]thymidine incorporation), but became stimulated when they were shifted to permissive temperature (32.58C) (48% stimulation of [ 3 H]thymidine incorporation). These results were con®rmed by cell number counts as can be seen in Figure 7 , where it is shown that over a 6 day period, untreated T12-neo control cells seeded at 5000 cells/ dish attained 133 250+5186 cells and 119 500+2398 cells at 378C and 32.28C respectively and TGF-b1 treated ones only 56250+1992 cells and 62175+893 cells respectively, whereas untreated T12-P53 cells attained 111 300+1877 cells and 87 175+2352 cells at 378C and 32.58C respectively and TGF-b1 treated ones attained only 61 175+1575 cells when they are maintained at 378C but went up to 136 000+1594 cells when they are shifted to 32.58C. These experiments strongly suggest that TGF-b1 requires a functional wild type P53 protein to stimulate the proliferation of the ®broblastic cell lines studied here and that an Figure 7 Eect of TGF-b1 on growth of T12, T12-neo and T12-P53 cells by cell number counts. Cells were seeded at 5000/dish (2 cm 2 ) in DMEM+2% NCS at 378C and on the next day 2 ng/ ml of TGF-b1 or control vehicle (HCl/BSA) were added. T12-neo and T12-P53 were maintained at restrictive temperature (378C) or shifted to permissive temperature (32.58C). These cultures were given a second dose of TGF-b1 (or control) on day 3 and cell counts were made on day 6. Each given value is the mean+s.d. of cell counts in four wells; the observed dierences between TGF-b1 treated cells and their controls were statistically signi®cant according to the t-test (P50.001) Figure 8 Expression studies of P53 in T12-neo and T12-P53 cells. T12-neo cells and T12-P53 cells were grown in DMEM+5% NCS at 378C or 32.58C and analysed for P53 expression by immunoprecipitation using the monoclonal anti-P53 PAb 122 antibody. For T12-neo cells, the same results were obtained at both temperatures. Here, we show those at 378C TGF-b1-growth stimulation of fibroblasts requires p53 F Dkhissi et al inversion of this growth response occurs if P53 is absent or inactivated by mutation or by complexing with viral oncoproteins.
Modulation by TGF-b1 of p21Waf and p27Kip in NIH3T3 and NIH-SV40 ®broblasts
To begin exploring the signalling pathways underlying the bifunctional eect of TGF-b1 on proliferation of the ®broblasts studied here, we examined the possible modulation by this growth factor of three cyclin kinase inhibitors, p21Waf, p27Kip and p15INK4B, in NIH3T3 and NIH-SV40 cells. As shown in Figure 9 a 24 h TGF-b1 treatment reduced the expression of p21Waf in NIH3T3 ®broblasts and increased it in their SV40-transformed counterparts. In the same experiment TGF-b1 induced a slight decrease in p27Kip level in NIH3T3 cells, without causing a notable change in NIH-SV40 cells, compared to untreated cells. No signi®cant eect of TGF-b1 treatment on p15INK4B, cdk2 or cdk4 levels was observed in NIH3T3 or NIH-SV40 cells (Figure 9 ) (except for a small reduction of cdk2 level in TGF-b1-treated NIH-SV40 cells compared to controls). The same TGF-b1 treatment did not aect pRB phosphorylation in either NIH3T3 or NIH3T3-SV40 cells (Figure 9 ), whereas in the same experiment such treatment did induce pRB hypophosphorylation in the Mink lung epithelial cell line, CCL64 (data not shown), in agreement with Laiho et al. (1990) .
Discussion
Our results show that the proliferation of NIH3T3 ®broblasts is stimulated by TGF-b1, but is inhibited when these cells are transformed by SV40. From¯ow cytometry measurements it was shown that apoptosis was not a signi®cant factor in explaining the reduced cell number in NIH-SV40 cultures treated with TGFb1 compared to controls. TGF-b1 also inhibited NIH3T3 ®broblasts when they were stably transfected with expression vectors coding for viral oncoproteins which complex with the P53 protein. Thus expression of LTag which binds both P53 and pRB, and LTag-K1 or E1B-55 kd which bind P53 but not pRB, causes an inversion of the TGF-b1-growth stimulation of these ®broblasts. Such an inversion of the TGF-b1 growth response is not observed when NIH3T3 ®broblasts are transfected with vectors expressing del-1137, an LTag mutant which still binds pRB but not P53, or E1A which binds pRB but does not bind to P53.
Therefore it appears that P53, which is wild type in NIH3T3 since it co-immunoprecipitates with Large T, is implicated in the TGF-b1-growth response towards these ®broblasts: when P53 is functional then TGF-b1 treatment causes stimulation of proliferation, but when it is complexed with viral oncoproteins known to bind and functionally inactivate P53, then the same growth factor treatment provokes inhibition. On the contrary, the binding of pRB to viral oncoproteins does not in¯uence the TGF-b1-mediated stimulation of proliferation in this system.
The conditional expression of P53 in T12 embryonic ®broblasts from a knockout mouse, originally lacking P53, reveals an intrinsic role of P53 in modulating the TGF-b1 growth response in the absence of viral oncoproteins. Indeed, T12 cells, 7/7 P53, are inhibited by TGF-b1, remain so after transfection with a ts P53 at restrictive temperature, but become stimulated by TGF-b1 when the same transfected cells are grown at permissive temperature where P53 is functional. Collectively, these data indicate that stimulation of proliferation by TGF-b1 of NIH3T3 and T12 ®broblasts requires the expression of a wild type P53 protein and that the latter's absence or inactivation at restrictive temperature or by complexing with viral oncoproteins provokes an inversion of the TGF-b1 growth response to one of inhibition. It is to note, in the context of growth-inhibition of ®broblasts by TGF-b1, our previous observation that human KHOS cells, originating from an osteosarcoma, and human RD cells, originating from a human rhabdomyosarcoma, both express a mutant form of P53 and are growth-inhibited by TGF-b1 (Raynal and Lawrence, 1995) . Our previous ®nding that WI38 fibroblasts, originating from a 3-month old human fetus, are growth-stimulated by TGF-b1 (Raynal et al., 1994) is in agreement with Hill et al. (1986) , who reported that human embryo ®broblasts from fetuses of less than 50 gm (approx 3 months gestation) are growthstimulated by TGF-b1. We also found that WI38 ®broblasts contain a wild type P53, so their stimulation by TGF-b1 supports and extends the results reported here with murine ®broblasts.
To our knowledge there is no clear, previous, evidence in the literature which connects the TGF-b1-growth response to mesenchymal cells and P53 status. As to such a connexion in other cells, Blaydes et al. (1995) found that thyroid epithelial cells bearing mutant forms of P53 were no longer growth-inhibited by TGF-b1. However, these authors also reported that the introduction of a dominant negative P53 mutant into one of their thyroid cell lines bearing a wild type P53, did not change its responsiveness to growth inhibition by TGF-b1. They concluded that P53 and TGF-b1 generate separate but interacting inhibitory signals and that P53 modulates but does not mediate the TGF-b1 response. Huang et al. (1994) , using a panel of colon carcinoma cells (i.e., epithelial cells), some of which were stimulated, while others were Figure 9 Eect of TGF-b1 on the level of synthesis of p15INK4B, p21Waf1, p27Kip, Cdk2 and Cdk4 and on pRB phosphorylation in NIH3T3 and NIH-SV40 cells. Cells were grown in DMEM+5% NCS, then serum deprived for 24 h to improve cell synchronization, after which they were treated (+) or not (7) with 2 ng/ml TGF-b1 for 24 h and subjected to Western blot analysis. (a) p15INK4B, p21Waf, p27Kip. (b) cdk2, cdk4, pRB TGF-b1-growth stimulation of fibroblasts requires p53 F Dkhissi et al inhibited by TGF-b1, found no connexion of these responses with P53, which was mutant and overexpressed in all the cell lines. Thus no particular, generalised link between TGF-b1-mediated signals and P53 status governing the TGF-b1-growth response is apparent in epithelial cells. In any case, we are concerned here with explaining why a connexion between TGF-b1 signalling and wild type P53 status seems to exist in ®broblasts whose proliferation is stimulated by the growth factor. Yet, for growth-inhibition of the ®broblasts used here it is clear that P53 is quite dispensable, since the proliferation of T12 cells from a P53-knockout mouse is inhibited by TGF-b1. It is also clear that in order to inhibit growth of ®broblasts containing a wild type P53, this protein must be inactivated by complexing with LTag or the E1B-55 kd oncoprotein. In contrast, the mink epithelial cell line CCL64, which is strongly inhibited by TGF-b1, loses its sensitivity towards this growth factor after its transfection with LTag (Laiho et al., 1990) . These authors found that in LTagtransfected CCL64 cells, TGF-b1 treatment maintained pRB hypophosphorylated but in some way this prevented the growth-suppressive form of pRB from exerting an inhibitory response. LTag and E1A each bind to the A/B pocket of hypophosphorylated pRB, preventing the sequestration of the E2F transcription factor and allowing gene transcription to proceed, followed by cell cycle transition into S phase (Whyte et al., 1988; DeCaprio et al., 1988) . Here, in LTag-transfected ®broblasts pRB should be unable to bind E2F, yet they are growth-inhibited by TGF-b1. This would suggest that TGF-b1 inhibits ®broblast proliferation via an pRB-independent pathway. But in E1A-transfected cells, in which pRB is again unable to sequester E2F, their growth remains stimulated by TGF-b1, like the NIH3T3 controls. Despite pRB being inactivated by a viral oncoprotein in both cases, the observed dierential TGF-b1-growth response can be explained in terms of P53 status. Thus, in LTagtransfected cells, not only pRB, but also P53, will be inactivated, leading to a TGF-b1 growth-inhibitory response, whereas in E1A-transfected cells P53 function will not be aected and would allow a growthstimulatory response. Thus, although pRB has been shown to be important in TGF-b1-mediated inhibition of the Mink lung epithelial cell line, CCL64 (Laiho et al., 1990) , our results using pRB-inactivating viral oncoproteins show that this is not the case for the murine ®broblasts used here. Other reports have indicated the existence of a pRB-independant pathway for TGF-b1-mediated inhibition of human keratinocytes (Koike et al., 1994) and breast cancer cells (Ong et al., 1991) .
Since neither P53 nor pRB appear to determine the growth-inhibitory response of TGF-b1 towards the murine ®broblasts used here, the essential question boils down to why are these cells stimulated by TGFb1 when they bear a wild type P53 protein? We propose that these data can be rationalized by taking into account the eect of TGF-b1 on p21Waf and possibly its slight eect on p27Kip levels. It is to note that p21Waf can be induced by wild type P53 (ElDeiry et al., 1993) and by a P53-independant mechanism (Michieli et al., 1994) . As shown in Figure 9 , TGF-b1 treatment decreases the levels of p21Waf and, to a much lesser extent, p27Kip in NIH3T3 ®broblasts, whereas p21Waf is strongly increased by TGF-b1 in their SV40-transformed counterparts, compared to controls, without a notable change in p27Kip levels. We recall that we have previously shown p21Waf repression in TGF-b1-stimulated WI38 human embryo ®broblasts and its induction in their TGF-b1-inhibited SV40-transformed counterparts (Raynal and Lawrence, 1995) . Moreover, the basal level of p21Waf in these human ®broblasts was much higher in the normal cells than in the SV40-transformed cells and the same holds here, respectively, for NIH3T3 and NIH-SV40 cells. It is pertinent here to mention that NIH3T3 and WI38 cells each grow more slowly than their SV40-transformed counterparts. At this point we recall also the ®nding by Ravitz et al. (1995) , that TGF-b1-mediated stimulation of murine C3H10T1/2 ®broblasts was associated with downregulation of p27Kip. Overall these data suggest that in NIH3T3 cells, the presence of wild type P53 allows a fairly high basal level of p21Waf and, assisted by the basal level of p27Kip, this would moderate their rate of growth, unless treated by TGF-b1 which strongly represses p21Waf and, more slightly, p27Kip, allowing proliferation to increase. In the SV40-transformed-, wild type LTagand E1B-transfected NIH3T3 ®broblasts, their wild type P53 is inactivated by the corresponding viral oncoprotein, preventing P53 from inducing a high level of p21Waf, consistent with their faster proliferation than the untransformed cells, even though the basal level of p27Kip is similar in the two cell types. When these oncoprotein-expressing cells are treated with TGF-b1, this induces p21Waf without notably increasing the amount of p27Kip, which restrain their growth. This schema requires TGF-b1 to have a signi®cant bifunctional eect on p21Waf synthesis. We have previously shown that TGF-b1 does, indeed, have such a bifunctional eect on p21Waf (Raynal and Lawrence, 1995) . The possibility that a TGF-b1-mediated eect on p27Kip is important cannot be excluded as the growth factor represses p27Kip in C3H10T1/2 ®broblasts (Ravitz et al., 1995) , although in proliferating Mink lung epithelial cells and in human keratinocytes (both growth inhibited by TGFb1) their already high basal level of p27Kip is not markedly increased by TGF-b1 (Reynisdottir et al., 1995) .
The cdk inhibitor p15INK4B is known to be implicated in the TGF-b1-mediated inhibition of human keratinocytes (Hannon and Beach, 1994) . However, in some human squamous cell carcinoma cell lines growth-inhibited by TGF-b1, p15INK4B was not induced by this factor and in others resistant to growth-inhibition by TGF-b1, the latter factor induced p15INK4B, indicating that this cdk inhibitor is not the major factor in mediating TGF-b1 inhibition of proliferation of these carcinoma-derived cell lines (Malliri et al., 1996) . Here, in NIH3T3 or NIH3T3-SV40 cells, TGF-b1 treatment did not aect p15INK4B levels, nor did it aect pRB phosphorylation or cdk2 or cdk4 levels, with the slight exception of a very modest drop in cdk2 level in TGF-b1-treated NIH-SV40 cells compared to untreated cells. Since we found that pRB-inactivating viral oncoproteins did not aect either the stimulatory or the inhibitory TGF-b1 TGF-b1-growth stimulation of fibroblasts requires p53 F Dkhissi et al response, the TGF-b1-mediated eects on the cdk inhibitor p21Waf and their modest eects on p27Kip would appear to act on proteins other than pRB. In the light of previous reports (see reviews by Alexandrow and Moses, 1995; MassagueÂ and Polyak, 1995; Heldin et al., 1997 ) the present study would support the notion that TGF-b1-mediated eects on proliferation act by dierent signalling mechanisms in dierent cell types. Finally, it is to be noted that stimulation of ®broblasts by TGF-b1, secreted locally by both normal and cancerous cells, would facilitate stroma formation, which is a prerequisite for tumour growth (Nagy et al., 1988) .
Materials and methods
Cells and media
Mouse NIH3T3 ®broblasts were provided by Dr GM Cooper (Sydney Farber Cancer Institute, Boston, MA, USA). The SV40-transformed NIH3T3 cell line (NIH-SV40) and the T12 embryonic ®broblast cell line, from a P53 knockout mouse (Donehover et al., 1992) , were obtained from Drs E and P May (CNRS, Fontenay-aux Roses, France). The routine culture of all cell types was made in DMEM (Gibco, Cergy-Pontoise, France) supplemented with 5% newborn calf serum (NCS) at 378C (except for the ts P53 mutant) in a 5% CO 2 atmosphere. Human recombinant TGF-b1 was purchased from R&D Systems (Oxford, UK) and solubilized in 4 mM HCl+1 mg/ml of bovine serum albumin (BSA).
Plasmids and DNA transfection
Seven plasmids were used for the transfection experiments. The pAS plasmid encodes the SV40 Large T antigen (Benoist and Chambon, 1981) ; LTag-K1 encodes the KI mutant LT antigen that does not bind pRb (Kalderon and Smith, 1984) ; LTag-del1137-neo encodes an aminoterminal deletion mutant LT antigen defective in binding to P53, together with a neomycin resistant gene (Pipas et al., 1983) ; pRSVneo-5SVE1B encodes the adenovirus 5 E1B-55 kd protein controlled by the SV40 early promotor and the neomycin resistant gene (Jochemsen et al., 1987) ; pRSV-E1A12S encodes the adenovirus type 2 E1A12S protein (kindly provided by Dr D Trouche, IFC-1, Villejuif, France); pMSVP53-val135 encodes a murine temperaturesensitive P53 mutant that contains valine in place of alanine at amino acid residue 135 (Finlay et al., 1988) and pWLneo (mammalian transfection kit, Stratagene).
Transfection of plasmids into the cells was performed by using a mammalian transfection kit (Stratagene) following the manufacturer's protocol. Brie¯y, the cells were seeded in 10 cm diam. plastic dishes at a density of 5610 5 cells/dish and transfected the following day with 25 mg of the corresponding plasmid together with 5 mg of pWLneo or with 15 mg for those plasmids encoding the desired oncoprotein and neomycin resitance. Cells were also transfected with pWLneo alone to obtain neo-control cells. Stable transfectants were selected by growth in 400 mg/ml G418. In each case three clones were characterised and the results presented here are for one clone representative of the other two.
DNA synthesis, cell number counts and¯ow cytometry
The eect of TGF-b1 on DNA synthesis in the various cell lines used here was measured by [ 3 H]thymidine incorporation and by cell number counts. For the ®rst case the cells were seeded in quadruplicate at 5610 4 per well (2 cm 2 ) in 24-well plates in 1.0 ml of DMEM with 5% NCS for 24 h and then cultured for 24 h without serum to improve the cell synchronization, after which they were treated with 2 ng/ml of TGF-b1 or control vehicule (HCl/BSA) in the presence of 5% NCS. Twenty-three hours later the cells were labelled for 1 h without changing the medium with 1 mCi/ml of [ 3 H]thymidine (82 Ci/mmol, NEN-France) and TCA-insoluble material counted as previously described (Benzakour et al., 1992) . The results are presented as the mean+s.d. of counts per minute (c.p.m.) measured in four wells. For growth tests by cell number counts, the cells were seeded in quadruplicate at 5000 per well (2 cm 2 ) in 1.0 ml of DMEM with 2% NCS and on the next day TGFb1 or control vehicle (HCl/BSA) were added as above. These cultures were given a second dose of TGF-b1 (or control) on day 3 and cell counts were made on day 6 using a haemocytometer. Each given value is the mean+s.d. of cell counts in four wells; the observed dierences between TGF-b1 treated cells and their controls were statistically signi®cant according to the t test (P50.001). Cell cycle phase distribution was determined by analytical DNA¯ow cytometry as described by Muller et al., (1975) and Gregoire et al., (1984) using a Coulter Epic Elite apparatus and software developed by PS Rabinovitch (Phoenix Flow System, San Diego, CA, USA). The percentage of apoptotic cells was determined by¯ow cytometry as described by Ormerod et al. (1992) and Dive et al. (1992) . Brie¯y, 10 6 untreated or TGF-b1 treated cells were resuspended in 1 ml PBS and incubated with 1 mg/ml Hoechst 33342 (Sigma) for 4 mn at 378C. The cells were cooled on ice and 10 mg/ml Propidium iodide (Sigma) were added. Apoptotic cells take up the Hoechst 33342 dye more rapidly than normal cells and dead cells can be distinguished by propidium iodide. The¯ow cytometer was used with a UV laser and blue (400 ± 500 nm) and red (more than 630 nm)¯uorescence recorded.
Immunoprecipitation of P53 and large T antigen
For these experiments cells were seeded at 5610 5 per 6 cm diam. dish in 5 ml of DMEM with 5% NCS; the next day the medium was changed to DMEM without serum, the cultures left for 24 h and then the cells were treated with 2 ng/ml TGF-b1 (or control vehicle) in the presence of 5% NCS for 24 h. During the last 3 h post-treatment these media were removed and the cells labelled in methionine-free DMEM with 5% dialysed NCS and 100 mCi/ml 35 S-methionine/cysteine mixture (NEN France), (or in 200 mCi/ml 32 P-orthophosphate (NEN France). All further steps (immunoprecipitation, electrophoresis) were as previously described (Raynal et al., 1994) . The PAb 122 and PAb 416 antibodies, which recognize P53 and LTag proteins, respectively, were used directly from the conditioned medium of the corresponding hybridoma at 10% ®nal concentration. On autoradiograms where the eets of TGF-b1 were not obvious by eye, two autoradiograms exposed for dierent times for each gel were scanned with a Pharmacia-LKB Ultrascan XL densitometer.
Western blotting
For Western blotting, cells were seeded as above and 24 h later, cell extracts were subjected to SDS ± PAGE on 10% gels and then the gels were transferred onto Immobilon 0.45 mm membranes (Millipore, France) using a Bio-Rad Trans-blot transfer cell. After transfer, the blots were blocked in PBS buer containing 5% non-fat dried milk. Following probing with primary and secondary antibodies, the blots were visualised by enhanced chemiluminescence (Amersham) and recorded with Kodak X-Omat AR ®lm. The primary antibodies against viral oncoproteins used in TGF-b1-growth stimulation of fibroblasts requires p53 F Dkhissi et al this study were: PAb 416 anti-LTag (10% of hybridoma supernatant); E1A-speci®c M73 antibody at 1/250 dilution and E1B 55 KD-speci®c A1C6 antibody, kindly supplied by Dr van der Eb (Sylvius Laboratories, Leiden, Netherlands) used directly from hybridoma supernatant at 25% ®nal concentration. Antibodies against cell cycle proteins were anti-p15INK4B, anti-p21Waf, anti-p27Kip, anti-cdk-2, anti-cdk-4 and anti-pRB (C15) from Santa Cruz (TEBUFrance) used at 1/1000 dilution, with the necessary goat, mouse or rabbit secondary antibody (Amersham-France) at 1/2500 dilution.
